The European Commission (EC) has granted marketing authorisation for Pierre Fabre’s Braftovi and Mektovi combination therapy for the treatment of adults with unresectable or metastatic melanoma with a BRAFV600 mutation.
Read More
US regulators have issued a green light for Pierre Fabre and Array Biotech’s encorafenib/binimetinib combination therapy for advanced BRAF-mutant melanoma.
Read More
Pierre Fabre and Array BioPharma have unveiled data from a late-stage trial showing a significant improvement in one-year survival in colorectal cancer patients taking encorafenib, binimetinib and cetuximab versus the standard of care.
Read More
